These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
187 related articles for article (PubMed ID: 23928902)
1. Recombinant trivalent influenza vaccine (flublok(®)): a review of its use in the prevention of seasonal influenza in adults. Yang LP Drugs; 2013 Aug; 73(12):1357-66. PubMed ID: 23928902 [TBL] [Abstract][Full Text] [Related]
2. Protective efficacy of a trivalent recombinant hemagglutinin protein vaccine (FluBlok®) against influenza in healthy adults: a randomized, placebo-controlled trial. Treanor JJ; El Sahly H; King J; Graham I; Izikson R; Kohberger R; Patriarca P; Cox M Vaccine; 2011 Oct; 29(44):7733-9. PubMed ID: 21835220 [TBL] [Abstract][Full Text] [Related]
3. Evaluation of the safety, reactogenicity and immunogenicity of FluBlok trivalent recombinant baculovirus-expressed hemagglutinin influenza vaccine administered intramuscularly to healthy children aged 6-59 months. King JC; Cox MM; Reisinger K; Hedrick J; Graham I; Patriarca P Vaccine; 2009 Nov; 27(47):6589-94. PubMed ID: 19716456 [TBL] [Abstract][Full Text] [Related]
4. Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices - United States, 2017-18 Influenza Season. Grohskopf LA; Sokolow LZ; Broder KR; Walter EB; Bresee JS; Fry AM; Jernigan DB MMWR Recomm Rep; 2017 Aug; 66(2):1-20. PubMed ID: 28841201 [TBL] [Abstract][Full Text] [Related]
5. Randomized comparison of the safety of Flublok(®) versus licensed inactivated influenza vaccine in healthy, medically stable adults ≥ 50 years of age. Izikson R; Leffell DJ; Bock SA; Patriarca PA; Post P; Dunkle LM; Cox MM Vaccine; 2015 Nov; 33(48):6622-8. PubMed ID: 26529070 [TBL] [Abstract][Full Text] [Related]
6. Safety, efficacy, and immunogenicity of Flublok in the prevention of seasonal influenza in adults. Cox MM; Izikson R; Post P; Dunkle L Ther Adv Vaccines; 2015 Jul; 3(4):97-108. PubMed ID: 26478817 [TBL] [Abstract][Full Text] [Related]
7. Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices, United States, 2021-22 Influenza Season. Grohskopf LA; Alyanak E; Ferdinands JM; Broder KR; Blanton LH; Talbot HK; Fry AM MMWR Recomm Rep; 2021 Aug; 70(5):1-28. PubMed ID: 34448800 [TBL] [Abstract][Full Text] [Related]
8. Systematic review of the efficacy, effectiveness and safety of recombinant haemagglutinin seasonal influenza vaccines for the prevention of laboratory-confirmed influenza in individuals ≥18 years of age. O Murchu E; Comber L; Jordan K; Hawkshaw S; Marshall L; O'Neill M; Ryan M; Teljeur C; Carnahan A; Pérez JJ; Robertson AH; Johansen K; Jonge J; Krause T; Nicolay N; Nohynek H; Pavlopoulou I; Pebody R; Penttinen P; Soler-Soneira M; Wichmann O; Harrington P Rev Med Virol; 2023 May; 33(3):e2331. PubMed ID: 35106885 [TBL] [Abstract][Full Text] [Related]
9. Live attenuated influenza vaccine (FluMist®; Fluenz™): a review of its use in the prevention of seasonal influenza in children and adults. Carter NJ; Curran MP Drugs; 2011 Aug; 71(12):1591-622. PubMed ID: 21861544 [TBL] [Abstract][Full Text] [Related]
10. Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices - United States, 2020-21 Influenza Season. Grohskopf LA; Alyanak E; Broder KR; Blanton LH; Fry AM; Jernigan DB; Atmar RL MMWR Recomm Rep; 2020 Aug; 69(8):1-24. PubMed ID: 32820746 [TBL] [Abstract][Full Text] [Related]
11. Randomized Comparison of Immunogenicity and Safety of Quadrivalent Recombinant Versus Inactivated Influenza Vaccine in Healthy Adults 18-49 Years of Age. Dunkle LM; Izikson R; Patriarca PA; Goldenthal KL; Muse D; Cox MMJ J Infect Dis; 2017 Dec; 216(10):1219-1226. PubMed ID: 28968871 [TBL] [Abstract][Full Text] [Related]